Info

🌱 來自: polycythemia vera (PV)

Treatment for JAK2 + PV

• Phlebotomy to goal Hct <45% (NEJM 2013;368:22), consider <42% in women
• Low-dose ASA in all Pts (NEJM 2004;350:114)
• Hydroxyurea if high risk of thrombosis (age ≥60, prior thrombosis) or if inadequate Hct by phlebotomy alone
• PEG IFN-alpha preferred in younger Pts and pregnancy (Lancet Haematol2017;4:e165)
• Ruxolitinib (JAK1/2 inhibitor) if refractory to or intolerant of hydroxyurea (NEJM 2015;372:426)
• Supportive: allopurinol (gout), H2-blockers/antihistamines (pruritus). Avoid iron supp.
• Data for optimal mgmt of other types of PV (secondary, germline, etc.) currently lacking